Arsenal Biosciences

Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer. With a programmable and computationally driven approach, the company aims for enhanced and broader activity and safety profile, designing medicines with multiple pharmaceutical functions to attack cancer's inherent multi-faceted nature. The team spans technology, biological sciences, clinical and manufacturing disciplines. Ken Drazan, MD serves as Chairman, CEO, and co-founder.

Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer. The company describes its approach as programmable and computationally driven, aiming for enhanced and broader activity and safety profile, and designing medicines with multiple pharmaceutical functions to attack cancer's inherent multi-faceted nature. Its team works across technology, biological sciences, clinical and manufacturing disciplines. Ken Drazan, MD is Chairman, CEO, and co-founder; Irene Pleasure, PhD, JD serves as General Counsel & Corporate Secretary.

Clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.

• 2020-10-21

  Teneobio and ArsenalBio enter research collaboration and license agreement[3]Teneobio与ArsenalBio达成研究合作及许可协议finanznachrichten.de

  Reported: 2020-10-21

  Teneobio announced that it had entered a research collaboration and commercial license agreement with ArsenalBio for the use of Teneobio's UniDabs in CAR T-cell therapy. ArsenalBio will have commercial rights to UniDabs against therapy-guiding antigens for one of its proprietary immune cell therapy programs.

1. 1Arsenal Bio • Engineering Hopearsenalbio.com
2. 2About • Arsenal Bioarsenalbio.com
3. 3Teneobio与ArsenalBio达成研究合作及许可协议finanznachrichten.de